BioCryst Pharmaceuticals | BCRX - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Chugai Pharma JPY 95M 260M 2025-12
Daiichi Sankyo JPY 2.16B 1.33B 2025-12
DBV Technologies USD 461K 323.71K 2025-03
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
Glaxosmithkline GBP 177.95M 6.05M 2025-09
Incyte USD 582K 10K 2025-12
Ionis Pharmaceuticals USD 18M 0 2025-12
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novavax USD 5.82M 342K 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12